Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
Abstract Immune deficits after CD19 chimeric antigen receptor (CAR) T‐cell therapy can be long‐lasting, predisposing patients to infections and non‐relapse mortality. In B‐cell non‐Hodgkin lymphoma (B‐NHL), the prognostic impact of immune reconstitution (IR) remains ill‐defined, and detailed cross‐p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | HemaSphere |
| Online Access: | https://doi.org/10.1002/hem3.70062 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850202447853649920 |
|---|---|
| author | Sophia Stock Veit L. Bücklein Viktoria Blumenberg Giulia Magno Alica‐Joana Emhardt Alessandra M. E. Holzem David M. Cordas dos Santos Christian Schmidt Stefanie Grießhammer Lisa Frölich Sebastian Kobold Michael vonBergwelt‐Baildon Kai Rejeski Marion Subklewe |
| author_facet | Sophia Stock Veit L. Bücklein Viktoria Blumenberg Giulia Magno Alica‐Joana Emhardt Alessandra M. E. Holzem David M. Cordas dos Santos Christian Schmidt Stefanie Grießhammer Lisa Frölich Sebastian Kobold Michael vonBergwelt‐Baildon Kai Rejeski Marion Subklewe |
| author_sort | Sophia Stock |
| collection | DOAJ |
| description | Abstract Immune deficits after CD19 chimeric antigen receptor (CAR) T‐cell therapy can be long‐lasting, predisposing patients to infections and non‐relapse mortality. In B‐cell non‐Hodgkin lymphoma (B‐NHL), the prognostic impact of immune reconstitution (IR) remains ill‐defined, and detailed cross‐product comparisons have not been performed to date. In this retrospective observational study, we longitudinally characterized lymphocyte subsets and immunoglobulin levels in 105 B‐NHL patients to assess patterns of immune recovery arising after CD19 CAR‐T. Three key IR criteria were defined as CD4+ T helper (TH) cells > 200/µL, any detectable B cells, and serum immunoglobulin G (IgG) levels >4 g/L. After a median follow‐up of 24.6 months, 38% of patients displayed TH cells, 11% showed any B cells, and 41% had IgG recovery. Notable product‐specific differences emerged, including deeper TH cell aplasia with CD28z‐ versus longer B‐cell aplasia with 41BBz‐based products. Patients with any IR recovery experienced extended progression‐free survival (PFS) (median 20.8 vs. 1.7 months, p < 0.0001) and overall survival (OS) (34.9 vs. 4.0 months, p < 0.0001). While landmark analysis at 90 days confirmed improved PFS in patients with any recovery (34.9 vs. 8.6 months, p = 0.005), no significant OS difference was noted. Notably, 72% of patients with refractory disease never displayed recovery of any IR criteria. Early progressors showed diminished IR at the time of progression/relapse compared to patients with late progression/recurrence (after Day 90). Our results highlight the profound immune deficits observed after CD19 CAR‐T and shed light on the intersection of IR and efficacy in B‐NHL. Importantly, IR was impaired considerably postprogression, carrying significant implications for subsequent T‐cell‐engaging therapies and treatment sequencing. |
| format | Article |
| id | doaj-art-47af631fe3324025aa5f5ba4e9f8fe0c |
| institution | OA Journals |
| issn | 2572-9241 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj-art-47af631fe3324025aa5f5ba4e9f8fe0c2025-08-20T02:11:46ZengWileyHemaSphere2572-92412025-01-0191n/an/a10.1002/hem3.70062Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphomaSophia Stock0Veit L. Bücklein1Viktoria Blumenberg2Giulia Magno3Alica‐Joana Emhardt4Alessandra M. E. Holzem5David M. Cordas dos Santos6Christian Schmidt7Stefanie Grießhammer8Lisa Frölich9Sebastian Kobold10Michael vonBergwelt‐Baildon11Kai Rejeski12Marion Subklewe13Department of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDivision of Clinical Pharmacology, Department of Medicine IV LMU University Hospital, LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyDepartment of Medicine III LMU University Hospital LMU Munich Munich GermanyAbstract Immune deficits after CD19 chimeric antigen receptor (CAR) T‐cell therapy can be long‐lasting, predisposing patients to infections and non‐relapse mortality. In B‐cell non‐Hodgkin lymphoma (B‐NHL), the prognostic impact of immune reconstitution (IR) remains ill‐defined, and detailed cross‐product comparisons have not been performed to date. In this retrospective observational study, we longitudinally characterized lymphocyte subsets and immunoglobulin levels in 105 B‐NHL patients to assess patterns of immune recovery arising after CD19 CAR‐T. Three key IR criteria were defined as CD4+ T helper (TH) cells > 200/µL, any detectable B cells, and serum immunoglobulin G (IgG) levels >4 g/L. After a median follow‐up of 24.6 months, 38% of patients displayed TH cells, 11% showed any B cells, and 41% had IgG recovery. Notable product‐specific differences emerged, including deeper TH cell aplasia with CD28z‐ versus longer B‐cell aplasia with 41BBz‐based products. Patients with any IR recovery experienced extended progression‐free survival (PFS) (median 20.8 vs. 1.7 months, p < 0.0001) and overall survival (OS) (34.9 vs. 4.0 months, p < 0.0001). While landmark analysis at 90 days confirmed improved PFS in patients with any recovery (34.9 vs. 8.6 months, p = 0.005), no significant OS difference was noted. Notably, 72% of patients with refractory disease never displayed recovery of any IR criteria. Early progressors showed diminished IR at the time of progression/relapse compared to patients with late progression/recurrence (after Day 90). Our results highlight the profound immune deficits observed after CD19 CAR‐T and shed light on the intersection of IR and efficacy in B‐NHL. Importantly, IR was impaired considerably postprogression, carrying significant implications for subsequent T‐cell‐engaging therapies and treatment sequencing.https://doi.org/10.1002/hem3.70062 |
| spellingShingle | Sophia Stock Veit L. Bücklein Viktoria Blumenberg Giulia Magno Alica‐Joana Emhardt Alessandra M. E. Holzem David M. Cordas dos Santos Christian Schmidt Stefanie Grießhammer Lisa Frölich Sebastian Kobold Michael vonBergwelt‐Baildon Kai Rejeski Marion Subklewe Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma HemaSphere |
| title | Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma |
| title_full | Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma |
| title_fullStr | Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma |
| title_full_unstemmed | Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma |
| title_short | Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma |
| title_sort | prognostic significance of immune reconstitution following cd19 car t cell therapy for relapsed refractory b cell lymphoma |
| url | https://doi.org/10.1002/hem3.70062 |
| work_keys_str_mv | AT sophiastock prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT veitlbucklein prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT viktoriablumenberg prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT giuliamagno prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT alicajoanaemhardt prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT alessandrameholzem prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT davidmcordasdossantos prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT christianschmidt prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT stefaniegrießhammer prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT lisafrolich prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT sebastiankobold prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT michaelvonbergweltbaildon prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT kairejeski prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma AT marionsubklewe prognosticsignificanceofimmunereconstitutionfollowingcd19cartcelltherapyforrelapsedrefractorybcelllymphoma |